Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00287820
Recruitment Status : Completed
First Posted : February 7, 2006
Last Update Posted : July 25, 2011
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by:
Nathan Kline Institute for Psychiatric Research

Brief Summary:

The primary objective of the study is to assess whether chronic treatment with olanzapine over a five-month period produces a significant increase in abnormalities in glucose levels. The main secondary objective is to evaluate whether the increase in glucose levels and rate of glucose abnormalities differs between Olanzapine and Risperidone during this treatment period. Additional secondary objectives of the study are to investigate similar questions with respect to glycohemoglobin, triglycerides and other measures of glucose and lipid metabolism.

We hypothesize that Olanzapine will not be inferior to Risperidone in extent of increase in the primary outcome measure of serum glucose, and secondary measures of glycohemoglobin, insulin and lipids.


Condition or disease Intervention/treatment Phase
Schizophrenia Diabetes Metabolic Syndrome Hyperglycemia Drug: Olanzapine Drug: olanzapine Drug: risperidone Phase 4

Detailed Description:

In the on-going study in progress we use an extensive battery of assessments to investigate a)fasting levels of glucose and lipids at baseline and monthly during 5 months of treatment, b) glucose tolerance tests to investigate glucose and insulin abnormalities after a glucose load at baseline and during study treatment, and c)the effects of treatment with olanzapine and risperidone of post prandial glucose metabolism after a fatty meal (as detailed in the body of the proposal). Recent studies have shown that increased postprandial lipidemia is an important feature of many patients with type 2 diabetes and atherosclerosis. In addition to the biochemical measures, we will also assess clinical effects (PANSS and CGI ratings) and other side-effects (weight gain, appetite, somnolence, and EPS and TD). The specific plan calls for inpatients in a tertiary care hospital to be randomly assigned to olanzapine or risperidone, using a stratified random assignment procedure, and treated for five months with either olanzapine or risperidone. We estimate that we will have to enroll a sample of approximately 50-55 patients to obtain 46 acceptable complete cases(as specified in proposal below). On the basis of preliminary results from our prior and ongoing studies we predict no significant increase in glucose abnormalities from baseline during chronic treatment with olanzapine and no significant differences in development of glucose abnormalities in patients in patient treated with olanzapine and risperidone.

Additional measures being investigated include: comparison of olanzapine and risperidone in glucose and lipid responses to a fatty meal, ghrelin changes in response to a fatty mean, and CRP and IL-6, and thyroid and prolactin response to five months of treatment with the two drugs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism
Study Start Date : February 2004
Actual Study Completion Date : September 2007

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 1
olanzapine
Drug: Olanzapine
olanzapine 5-40 mg/day
Other Name: ayprexa

Drug: olanzapine
olanzapine 5-40 ,mg/day
Other Name: zyprexa

Active Comparator: 2
risperidone
Drug: risperidone
risperidone 1-12 mg/day
Other Name: riperidal




Primary Outcome Measures :
  1. Serum glucose [ Time Frame: during 5 months of treatment compared to baseline ]
  2. Hb1AC [ Time Frame: during 5 months of treatment compared to baseline ]
  3. triglycerides [ Time Frame: during 5 months of treatment compared to baseline ]
  4. cholesterol [ Time Frame: during 5 months of treatment compared to baseline ]
  5. insulin [ Time Frame: during 5 months of treatment compared to baseline ]
  6. c-peptide [ Time Frame: during 5 months of treatment compared to baseline ]

Secondary Outcome Measures :
  1. ghrelin [ Time Frame: during 5 months of treatment compared to baseline ]
  2. CRP [ Time Frame: during 5 months of treatment compared to baseline ]
  3. Thyroid hormones [ Time Frame: during 5 months of treatment compared to baseline ]
  4. prolactin [ Time Frame: during 5 months of treatment compared to baseline ]
  5. Il-6 [ Time Frame: during 5 months treatment compared to baseline ]
  6. PANSS scores [ Time Frame: during 5 months of treatment compared to baseline ]
  7. CGI score [ Time Frame: during 5 months of treatment compared to baseline ]
  8. EPS scores [ Time Frame: during 5 months of treatment compared to baseline ]
  9. TD Scores [ Time Frame: during 5 months of treatment compared to baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis
  • Schizophrenia or schizoaffective psychosis
  • 18-65 years of age

Exclusion Criteria:

  • Currently being treated with oral antidiabetics or insulin

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00287820


Locations
Layout table for location information
United States, New York
Manhattan Psychaitric Center
New York, New York, United States, 10035
Sponsors and Collaborators
Nathan Kline Institute for Psychiatric Research
Eli Lilly and Company
Investigators
Layout table for investigator information
Principal Investigator: Robert C Smith, MD PhD NYU Medical School, Dept of Psychiatry and Manhattan Psychiatric Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Robert C. Smith MD, Manhatan Psychiatric Center
ClinicalTrials.gov Identifier: NCT00287820    
Other Study ID Numbers: FiD-MC-x226(7524)
First Posted: February 7, 2006    Key Record Dates
Last Update Posted: July 25, 2011
Last Verified: December 2007
Keywords provided by Nathan Kline Institute for Psychiatric Research:
schizophrenia
diabetes
metabolic syndrome
hyperglycemia
glucose
insulin
lipids
IL-6
prolactin
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Hyperglycemia
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Olanzapine
Risperidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators